

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科伦博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 29, 2026**

References are made to the notice and circular (the “**Circular**”) of the annual general meeting (the “**AGM**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) dated June 4, 2026. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce the poll results of the AGM held at 10:00 a.m. on June 29, 2026 at Meeting Room 1, 2/F, K1 Building, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, the People's Republic of China.

Poll Results of Resolutions Proposed at the AGM

Resolutions of the AGM were voted on by poll. The voting results of the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the report of the Board of Directors for the year 2025.	165,102,492 (99.983413%)	0 (0.000000%)	27,390 (0.016587%)

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
2.	To receive the consolidated financial statements of the Group for the year 2025 audited by KPMG (the “ 2025 Financial Statements ”), together with the independent auditor’s report of the 2025 Financial Statements.	165,102,492 (99.983413%)	0 (0.000000%)	27,390 (0.016587%)
3.	To consider and approve the re-appointment of KPMG as the auditors of the Company for the year 2026, and to authorize the Board of Directors to determine the specific matters, including but not limited to their remuneration of not more than RMB2,800,000 for the year 2026 before tax, in relation to such appointment, with the details as set out in the Circular.	165,104,572 (99.984673%)	1,310 (0.000793%)	24,000 (0.014534%)
4.	To consider and approve the annual profit distribution plan of the Company for the year 2025, with the details as set out in the Circular.	165,105,882 (99.985466%)	0 (0.000000%)	24,000 (0.014534%)
5.	To consider and approve the acquisition of wealth management products with idle self-owned funds for the year 2026, with the details as set out in the Circular.	159,692,379 (96.707136%)	5,413,503 (3.278330%)	24,000 (0.014534%)
SPECIAL RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
6.	To consider and approve the grant of a general mandate to the Board to issue Shares and sell Treasury Shares, with the details of the general mandate as set out in the Circular.	159,194,196 (96.405444%)	5,910,376 (3.579229%)	25,310 (0.015327%)
7.	To consider and approve the grant of a general mandate to the Board to repurchase H Shares, with the details of the general mandate as set out in the Circular.	165,103,477 (99.984010%)	1,095 (0.000663%)	25,310 (0.015327%)

Notes:

- (a) As more than one-half of the votes were cast in favour of resolutions 1 to 5 of the AGM, the said resolutions were duly passed as ordinary resolutions of the Company.
- (b) As above two-thirds of the votes were cast in favour of resolutions 6 to 7 of the AGM, the said resolutions were duly passed as special resolutions of the Company.
- (c) As at the date of the AGM, the total number of issued Shares of the Company was 233,185,969 Shares, consisting of 62,201,712 Domestic Shares and 170,984,257 H Shares.
- (d) The total number of Shares of the Company entitling the holders to attend and vote on resolutions 1 to 7 at the AGM was 233,185,969 Shares, consisting of 62,201,712 Domestic Shares and 170,984,257 H Shares. Shareholders (or their proxies) attending the AGM held 165,129,882 Shares in aggregate entitling them to vote on resolutions 1 to 7, representing approximately 70.814673% of the total number of Shares of the Company entitling the holders to attend and vote on such resolutions.
- (e) None of the Shares of the Company entitling the holders to attend the AGM required the holders to abstain from voting in favour of the resolutions pursuant to Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
- (f) Save as disclosed above, none of the Shareholders of the Company have stated their intention in the Circular to vote against or abstain from voting on any of the resolutions at the AGM.
- (g) The convening of and the procedure for the holding of the AGM was in compliance with the requirements of PRC laws, administrative regulations and the Articles of Association.
- (h) The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited, and two representatives of the Shareholders acted as the counters and scrutineers for the vote-taking at the AGM.
- (i) The following Directors of the Board of the Company attended the AGM either in person or through video or teleconference: Mr. LIU Gexin, chairman of the Board and non-executive Director; Dr. GE Junyou, executive Director; Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo, non-executive Directors; and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong, independent non-executive Directors.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, June 29, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.